Navigation Links
PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant
Date:7/31/2008

DuraClean(TM) to Launch in Multiple Markets, Including Industrial

Contracted Services

SAN DIEGO, July 31 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced an agreement with DuraBan International Inc for distribution of PURE's silver dihydrogen citrate (SDC)-based disinfectant under DuraBan's DuraClean(TM) brand.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

DuraBan International Inc, a Minneapolis based chemical manufacturer specializing in earth-friendly antimicrobial technologies, intends to sell DuraClean through its existing distribution channels into multiple markets, including the building, consumer products, medical, service and industrial sectors.

Robert Dahl, founder of DuraBan, commented, "DuraBan's foundation has been built on providing earth-friendly antimicrobial solutions, of which SDC powered DuraClean is a perfect example. We expect it to provide an attractive, effective and efficient solution for our customers, as DuraBan stays true to its heritage of providing safe, effective and efficient solutions to our customers in the worldwide consumer, industrial and medical marketplace."

Michael L. Krall, President and CEO of PURE Bioscience, stated, "SDC is a perfect complement for DuraBan's product line, which features safe and green antimicrobial barrier technologies. DuraClean will be marketed through DuraBan's established distribution channels. These channels include a wide variety of markets, some of which will be significant new entry points for our SDC-based disinfectant, such as the industrial contracted services area."

DuraBan has registered DuraClean with the US EPA as a sub-registrant of PURE Bioscience and is currently undergoing registration in all 50 states. In accordance with the agreement, each bottle of DuraClean features PURE's "Powered by SDC" logo. The contract also provides for increasing annual minimum purchases; other specific terms of the contract were not disclosed.

DuraClean disinfectant carries a 30 second kill time on standard indicator bacteria, a 24 hour residual kill on standard indicator bacteria, a 2 minute kill time on some resistant strains of bacteria, 10 minute kill time on fungi, 30 second kill time on HIV Type I, and 10 minute kill time on other pathogenic viruses. These claims distinguish the efficacy of DuraClean from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings. Based on the EPA toxicity ratings from Category I (high toxicity) down to Category IV, DuraClean is a Category IV antimicrobial for which precautionary labeling statements are not required. This compares with Category II warning statements for most leading brands of disinfectant products.

About DuraBan

DuraBan International Inc, is a Minneapolis, Minn., based chemical manufacturer and emerging global innovator of built-in, earth-friendly, antimicrobial product protection. DuraBan engineers safe and durable antimicrobial solutions for consumer, industrial and medical products around the world. Its technology can be engineered into a variety of surfaces and materials including: coatings, polymers, textiles, lumber, plastic and adhesives. Built-in to products during the manufacturing process, DuraBan antimicrobial product protection inhibits the growth of microbes, such as bacteria, mold and mildew that can cause stains, odors and product deterioration. DuraBan's proprietary and patented antimicrobial technologies deliver unmatched performance, durability and efficacy through a unique formulation based on surface-modifying nanotechnology. Once applied, DuraBan chemically bonds to the product surface, creating a permanent antimicrobial barrier that destroys microorganisms upon contact. DuraBan's antimicrobial has never been shown to allow or cause microbial adaptation, resistance, mutation, diffusion, or migration and easily bonds to almost any surface, creating unlimited applications for this breakthrough technology. For more information, please visit http://www.durabanintl.com.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

PURE Bioscience Investor Contact:

Paul G. Henning, Vice President

Cameron Associates

(212) 554-5462

paul@cameronassoc.com


'/>"/>
SOURCE PURE Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):